Nattero G, Lisino F, Brandi G, Gastaldi L
Minerva Med. 1976 Jun 2;67(28):1871-5.
The results of many researches on migraine pathogenesis and our knowledge of the pharmacological action of reserpine led us to start using it in migraine prophylaxis ten years ago. For this purpose, standardized cycles of twenty administrations--heach dose being of 0.20 mg--were given intravenously; each cycle lasted a period of six to eight weeks. The positive data obtained on 300 patients suffering from severe migraine resulted statistically significant. Then, a double-blind clinical trial was carried out in Turin in agreement with a double-blind biochemical trial carried out in Copenhagen by Fog-Møller, Dalsgaard-Nielsen, Byrndum and Kemp Genefke. The results obtained have confirmed the efficacy of reserpine administered in appropriate doses and enabled the demonstration of its pharmacological mechanism. The results obtained also in "tension-vascular headache" with reserpine treatment were reviewed retrospectively and were highly significant.
许多关于偏头痛发病机制的研究结果以及我们对利血平药理作用的了解，促使我们在十年前开始将其用于偏头痛的预防。为此，静脉注射了二十次标准化疗程（每次剂量为0.20毫克）；每个疗程持续六至八周。在300名重度偏头痛患者身上获得的阳性数据在统计学上具有显著意义。然后，在都灵进行了一项双盲临床试验，这与Fog-Møller、Dalsgaard-Nielsen、Byrndum和Kemp Genefke在哥本哈根进行的一项双盲生化试验相一致。所获得的结果证实了适当剂量的利血平的疗效，并能够证明其药理机制。对利血平治疗“紧张性血管性头痛”所获得的结果也进行了回顾性分析，结果非常显著。
